05/03/2026
Ottawa, Ontario — Thursday March 5, 2026
Families with rare diseases often spend years searching for an answer. For Dr. Kiran Polavarapu, that journey is what drives his work—and why he has joined the CHEO Research Institute and the Brain-Heart Interconnectome (BHI) as a genomics and clinical bioinformatics Scientist to advance genomic discovery and improve diagnostic outcomes for children and families with complex neuromuscular and neurodevelopmental disorders.
“I am inspired by patients and families with rare diseases who spend years without a diagnosis,” said Dr. Polavarapu. “Seeing how a genetic diagnosis can end uncertainty, leading to treatment, and connect families to appropriate care is a strong motivation for my work.”
Dr. Polavarapu’s research integrates deep clinical phenotyping, genomics and transcriptomics and functional validation to improve diagnostic yield, enable novel gene discovery, and develop open‑source workflows for inherited neuromuscular disorders—including multisystem brain–heart–muscle phenotypes, aligning closely with the scientific priorities of the BHI.
With dual training in clinical neurology and genomic science, he has contributed to the analysis of more than 3,000 neuromuscular disease cases and helped establish over 1,000 genetic diagnoses—experience he brings to CHEO RI’s collaborative, translational genetic research environment.
“CHEO RI offers a unique research environment combining clinical care, discovery and translational approach to advance rare disease research for children. I’m inspired by the collaborative culture and the opportunity to be involved in initiatives like BHI while working along with world leaders in neuromuscular and rare disease genetics research like Dr. Hanns Lochmüller and Dr. Kym Boycott.” Dr. Polavarapu added.
Kiran aims to accelerate answers for families with rare diseases by uniting clinical insight with advanced genomic and bioinformatic approaches—bringing new avenues for discovery and diagnosis.